Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Oct:127:26-36.
doi: 10.1016/j.bone.2019.05.021. Epub 2019 May 22.

The clinical impact and biological mechanisms of skeletal muscle aging

Affiliations
Review

The clinical impact and biological mechanisms of skeletal muscle aging

Zaira Aversa et al. Bone. 2019 Oct.

Abstract

Skeletal muscle is a highly plastic tissue that remarkably adapts to diverse stimuli including exercise, injury, disuse, and, as discussed here, aging. Humans achieve peak skeletal muscle mass and strength in mid-life and then experience a progressive decline of up to 50% by the ninth decade. The loss of muscle mass and function with aging is a phenomenon termed sarcopenia. It is evidenced by the loss and atrophy of muscle fibers and the concomitant accretion of fat and fibrous tissue. Sarcopenia has been recognized as a key driver of limitations in physical function and mobility, but is perhaps less appreciated for its role in age-related metabolic dysfunction and loss of organismal resilience. Similar to other tissues, muscle is prone to multiple forms of age-related molecular and cellular damage, including disrupted protein turnover, impaired regenerative capacity, cellular senescence, and mitochondrial dysfunction. The objective of this review is to highlight the clinical consequences of skeletal muscle aging, and provide insights into potential biological mechanisms. In light of population aging, strategies to improve muscle health in older adults promise to have a profound public health impact.

Keywords: Autophagy; Exercise; Mitochondria; Physical function; Sarcopenia; Senescence; Strength.

PubMed Disclaimer

Conflict of interest statement

Declaration of interest

N.K. LeBrasseur has a financial interest related to this work: patents on senolytic drugs are held by Mayo Clinic. This work has been revised by the Mayo Clinic Conflict of Interest Review Board and was conducted in compliance with Mayo Clinic conflict of interest policies. No other conflicts of interest, financial or otherwise, are declared by the authors.

Figures

Figure 1.
Figure 1.. Age-related changes in skeletal muscle.
The considerable loss of muscle mass and volume with advancing age is attributed to both the loss and atrophy of muscle fibers. The progressive decrease in functional contractile tissue is matched with the accretion of fat and fibrotic tissue. These alterations, along with progressive loss of innervating motor neurons and capillaries, contribute to the age-related loss of muscle strength, power, and endurance.
Figure 2.
Figure 2.. Skeletal muscle in health, aging and disease.
Skeletal muscle uniquely generates force and power for diverse forms of physical function, including mobility. It is also a critical metabolic organ that is responsible for the storage of glucose, the oxidation of fatty acids, and is a rich source of amino acids. Based on its size and metabolic activity during both rest and movement, muscle strongly influences both resting energy expenditure (REE) and activity associated energy expenditure (REE). Measures of muscle performance, physical function, and mass are also determinants of physical resilience, the capacity to resist and recover from diverse challenges.

Similar articles

Cited by

References

    1. Rosenberg IH, Sarcopenia: origins and clinical relevance, J Nutr 127(5 Suppl) (1997) 990S–991S. - PubMed
    1. Lexell J, Taylor CC, Sjostrom M, What is the cause of the ageing atrophy? Total number, size and proportion of different fiber types studied in whole vastus lateralis muscle from 15- to 83-year-old men, J Neurol Sci 84(2-3) (1988) 275–94. - PubMed
    1. Cooper C, Fielding R, Visser M, van Loon LJ, Rolland Y, Orwoll E, Reid K, Boonen S, Dere W, Epstein S, Mitlak B, Tsouderos Y, Sayer AA, Rizzoli R, Reginster JY, Kanis JA, Tools in the assessment of sarcopenia, Calcif Tissue Int 93(3) (2013) 201–10. - PMC - PubMed
    1. Reginster JY, Cooper C, Rizzoli R, Kanis JA, Appelboom G, Bautmans I, Bischoff-Ferrari HA, Boers M, Brandi ML, Bruyere O, Cherubini A, Flamion B, Fielding RA, Gasparik AI, Van Loon L, McCloskey E, Mitlak BH, Pilotto A, Reiter-Niesert S, Rolland Y, Tsouderos Y, Visser M, Cruz-Jentoft AJ, Recommendations for the conduct of clinical trials for drugs to treat or prevent sarcopenia, Aging Clin Exp Res 28(1) (2016) 47–58. - PMC - PubMed
    1. Buckinx F, Landi F, Cesari M, Fielding RA, Visser M, Engelke K, Maggi S, Dennison E, Al-Daghri NM, Allepaerts S, Bauer J, Bautmans I, Brandi ML, Bruyere O, Cederholm T, Cerreta F, Cherubini A, Cooper C, Cruz-Jentoft A, McCloskey E, Dawson-Hughes B, Kaufman JM, Laslop A, Petermans J, Reginster JY, Rizzoli R, Robinson S, Rolland Y, Rueda R, Vellas B, Kanis JA, Pitfalls in the measurement of muscle mass: a need for a reference standard, J Cachexia Sarcopenia Muscle 9(2) (2018) 269–278. - PMC - PubMed

Publication types